Depomed Inc. (DEPO) Jumps 7.76% on February 17

Equities Staff |

Depomed Inc. (DEPO) was among the biggest gainers on the Russell 2000 for Wednesday February 17 as the stock popped 7.76% to $17.77, representing a gain of $1.28 per share. Some 1.17 million shares traded hands on 8,596 trades, compared with an average daily volume of 1.82 million shares out of a total float of 60.48 million. The stock opened at $16.73 and traded with an intraday range of $17.79 to $16.40.

After today's gains, Depomed Inc. reached a market cap of $1.07 billion. Depomed Inc. has had a trading range between $33.74 and $13.27 over the last year, and it had a 50-day SMA of $16.93 and a 200-day SMA of $22.02.

The stock has a P/E Ratio of 35.1.

DepoMed Inc is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system.

Depomed Inc. is based out of Newark, CA and has some 324 employees. Its CEO is James A. Schoeneck.

For a complete fundamental analysis analysis of Depomed Inc., check out Equities.com’s Stock Valuation Analysis report for DEPO. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Uber

Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…